Publications by authors named "Scott D Lunin"

Claim this Profile
U
Ublituximab plus ibrutinib versus ibrutinib alone for patients with relapsed or refractory high-risk chronic lymphocytic leukaemia (GENUINE): a phase 3, multicentre, open-label, randomised trial.
Jeff P Sharman, Danielle M Brander, Anthony R Mato, Nilanjan Ghosh, Stephen J Schuster, Scott D Lunin

Lancet Haematol· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
DYNAMO: A Phase II Study of Duvelisib (IPI-145) in Patients With Refractory Indolent Non-Hodgkin Lymphoma.
Ian W Flinn, Carole B Miller, Kirit M Ardeshna, Scott Tetreault, Sarit E Assouline, Scott D Lunin

J Clin Oncol· April 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dose, schedule, safety, and efficacy of guadecitabine in relapsed or refractory acute myeloid leukemia.
Gail J Roboz, Hagop M Kantarjian, Karen W L Yee, Patricia L Kropf, Casey L O'Connell, Scott D Lunin

Cancer· January 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis